1Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc), 2003,39 Suppl C:1-16.
2McLaughlin P, Cabanillas F, Grillo-Lopez AJ, et al. IDEC-C2B8 anti-CD20 antibody: final report on a Phase Ⅲ pivotal trials in patients with relapsed low-grade follicular lymphoma. Blood, 1996,88: 90a .
3Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma, 2004, 45: 205-219.
4Coiffier B, Haioun C, Ketterer N, et al. Rituximab ( anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study. Blood, 1998,92: 1927-1932.
5Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis, 2005, 64:913-920.
6Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol, 2004, 84:232-235.
7Mantadakis E, Danilatou V, Stiakaki E, et al. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.Am J Hematol, 2004, 77:303-310.
8Keating M J, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study. Blood, 2002, 99: 3554-3561.
9Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs, 2003,63: 1229-1243.
10Uppenkamp M, Engert A, Diehl V,et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-and low-grade non-Hodgkin' s lymphomas: a multicenter phase Ⅰ/Ⅱ study. Ann Hematol, 2002, 81:26-32.
2Nemecek ER,Matthews DC.Antibody-based therapy of human leukemia[J].Curr Opin Hematol,2002,9(4):316-21.
3Syrigos KN,Pliarchopoulou K,Harrington KJ.The development of monoclonal antibody therapy in leukemias[J].Hybridoma,2001,20(3):145-8.
4Ruffner KL,Matthews DC.Current uses ofmonoclonal antibodies in the treatment of acute leukemia[J].Semin Oncol,2000,27(5):531-9.
5Sandmaier BM,Bethge WA,Wilbur DS,et al.Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts[J].Blood,2002,100(1):318-26.
6Matthews DC,Appelbaum FR,Eary JF,et al.Phase I study of 131Ianti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome[J].Blood,1999,94(4):1237-47.
7Vallera DA,Elson M,Brechbiel MW,et al.Preclinical studies targeting normal and leukemic hematopoietic cells with yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice[J].Cancer Biother Radiopharm.2003,18(2):133-45.
8Hnatowich DJ,Virzi F,Doherty PW.DTPA-coupled antibodies labeled with yttrium-90[J].J Nucl Med,1985,26(5):503-9.
